On May 16, the European Medicines Agency (EMA) confirmed that after a long hiatus (punctuated only by COVID-related publications), Policy 0070 will officially resume in September 2023.
What does this mean for clinical trial sponsors?
For the first time, you may have to balance all three regulatory requirements – EMA Policy 0070, EU CTR, and Health Canada’s PRCI.
Join Niamh McGuinness, Senior Advisor, Clinical Trial Transparency and Privacy, to learn more about:
- The key points of EMA’s announcement
- What this means for your ongoing transparency initiatives
- How Privacy Analytics’ complete solution for clinical document submissions can help you meet the demands of all three requirements